A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1521-1526

  Itani, Yoshio ^a   Hosokawa, Kenichi ^b   Ito, Kimihiko ^c   Takeuchi, Satoshi ^d   Tabata, Tsutomu ^e   Tsubamoto, Hiroshi ^f   Fujita, Hiroyuki ^g   Akiyama, Minoru ^h   Adachi, Susumu ^f,i  

^a NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KANSAI ROSAI HOSPITAL   (Japan)

^d Department of Pediatric Surgery   (Japan)

^e MIE UNIVERSITY   (Japan)

^f HYOGO COLLEGE OF MEDICINE   (Japan)

^g KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^h SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

ⁱ ELI LILLY AND COMPANY   (United States)

Author keywords

Docetaxel; Epithelial ovarian cancer; Gemcitabine; Phase I II study; Treatment resistant

Indexed keywords

DOCETAXEL; GEMCITABINE;

ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TAXOIDS;

EID: 67650071105     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 329: 1550-1559, 1993.
2. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389-393, 1991.
3. Markman M and Bookman MA: Second-line treatment of ovarian cancer. The Oncologist 5: 26-35, 2000.
4. Gore ME, Fryatt I, Wiltshaw E and Dawson T: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36: 207-211, 1990. (Pubitemid 20061287)
5. Eisenhuaer EA: Docetaxel: Current status and future prospects. J Clin Oncol 13: 2865-2868, 1995.
6. Huang P, Chubb S, Hertel LW and Grindey GB: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
7. Verschraegen CF, Sittisomwong T, Kudelka AP, Guedes EP, Steger M, Nelson-Taylor T, Vincent M, Rogers R, Atkinson EN and Kavanagh JJ: Docetaxel for patients with paclitaxel-resistant müllerian carcinoma. J Clin Oncol 14: 2733-2739, 2000. (Pubitemid 30463556)
8. Kavanagh JJ, Kudelka AP, de Leon CG, Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen P, Edwards CL, Freedman RS and Verschraegen CF: Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2: 837-842, 1996. (Pubitemid 26168936)
9. Piccart MJ, Gore M, Ten Bokkel Huinink W, Van Oosterom A, Verweij J, Wanders J, Franklin H, Bayssas M and Kaye S: Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 87: 676-681, 1995.
10. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Phillips M and Hakes T: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12: 2301-2308, 1994. (Pubitemid 24346699)
11. Lund B, Hansen OP, Theilade K, Hansen M and Neijt JP: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533, 1994. (Pubitemid 24330217)
12. D'Agostino G, Amant F, Berteloot P, Scambia G and Vergote I: Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 88: 266-269, 2003. (Pubitemid 36331977)
13. Shapiro J, Millward MJ, Rschinn D, Michael M, Walcher V, Francis PA and Toner GC: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89-93, 1996. (Pubitemid 26337972)
14. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R and Spriggs DR: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20: 2824-2831, 2002. (Pubitemid 34651511)
15. Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A and Kalofonos HP: Gemcitabine and docetaxel as second-line chemotherapy for patients with non-small cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 92: 2902-2910, 2001. (Pubitemid 33091927)
16. Spiridonidis CH, Laufman LR, Jones J, Rhodes VA, Wallace K, and Nicol S: Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 16: 3866-3873, 1998. (Pubitemid 29001540)
17. Leu KM, Ostruszka LJ, Shewach D, Zalupski M, Sondak V, Biermann JS, Shin-Jung Lee J, Couwlier C, Palazzolo K and Baker LH: Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of arcoma. J Clin Oncol 22: 1706-1712, 2004. (Pubitemid 41079810)
18. Hukuda H and Saijo N: National Cancer Institute-Common Toxicity Criteria (NCI-CTC ver2.0) JCOG version. Jpn J Cancer Chemother 28: 1993-2027, 2001.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
20. Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H and Lambert HE: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14: 1545-1551, 1996. (Pubitemid 26134212)
21. Thigpen JT, Blessing JA, Ball H, Hummel SJ and Barrett RJ: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12: 1748-1753, 1994. (Pubitemid 24349373)
22. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E; AGO-OVAR; NCIC CTG; EORTC GCG: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699-4707, 2006.
23. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106, 2003.
24. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, Wang Y, Scribner DR Jr, Marciniack M, Naumann RW and Secord AA: Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25: 2811-2818, 2007. (Pubitemid 47123191)
25. Petra E, Angleitner-Boubenizek L, Reinthaller A, Deibl M, Zeimet AG, Volgger B, Stempfl A and Marth C: Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol 102: 226-229, 2006. (Pubitemid 44063577)
26. Sehouli J, Stengel D, Oskay G, Camara O, Hindenburg H J, Klare P, Blohmer J, Heinrich G, Elling D, Ledwon P and Lichtenegger W: A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Ann Oncol 13: 1749-1755, 2002. (Pubitemid 35439455)
27. Garcia A, AnneO'Meara, Bahador A, Facio G, Jeffers S, Kim DY and Roman L: Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Gynecol Oncol 93: 493-498, 2004. (Pubitemid 38507624)
28. Skarlos DV, Kalofonos HP, Fountzilas G, Dimopoulos MA, Pavlidis N, Razis E, Economopoulos T, Pectasides D, Gogas H, Kosmidis P, Bafaloukos D, Klouvas G, Kyratzis G and Aravantinos G: Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/ refractory to platinum and/or taxane's. A HeCOG phase II study. Anticancer Res 25: 3103-3108, 2005. (Pubitemid 41044707)
29. Gordon AN, Tonda M, Sun S and Rackoff W: Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95: 1-8, 2004.
30. Aravantinos G, Bafaloukos D, Fountzilas G, Christodoulou C, Papadimitriou C, Pavlidis N, Kalofonos HP, Gogas H, Kosmidis P and Dimopoulos MA: Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol 14: 1094-1099, 2003. (Pubitemid 36950174)
31. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA and Toner GC: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89-93, 1996. (Pubitemid 26337972)
32. Silver DF and Piver MS: Gemcitabine salvage chemotherapy for patients with gynecologic malignancues of the ovary. Fallopian tube, and peritoneum. Am J Clin Oncol 22: 450-452, 1999. (Pubitemid 30263289)
33. Markman M, Zanotti K, Webster K, Peterson G, Kulp B and Belinson J: Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol 91: 573-576, 2003. (Pubitemid 38388153)
34. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R and McGuire W: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186, 2007. (Pubitemid 350232248)